期刊文献+

炭疽保护性抗原与炭疽毒素受体结合特征分析

Analysis on characteristics of binding of anthrax protective antigen and anthrax toxin receptors
原文传递
导出
摘要 目的:建立检测炭疽毒素保护性抗原(PA)与靶细胞受体(ATR)结合能力的Binding-ELISA方法,并对两者结合特征进行分析。方法:以ELISA实验为基础,建立PA与ATR结合的体外模型,并对实验中的反应条件进行优化。采用Binding-ELISA方法,通过测定不同包被蛋白、不同二价阳离子条件下的D450以及相对饱和度等参数,分析PA与两种ATR的结合特征。结果与结论:以重组PA作为包被抗原时灵敏度更高,包被浓度为2μg/ml;二价阳离子浓度为5 mmol/L。两种受体与PA的亲和力不同,其中CMG2与PA的结合能力更强;并且两者与PA结合时离子依赖特征不同,PA与TEM8的结合能力在Mn2+存在时最强,PA与CMG2的结合能力在Ca2+存在时最强。这一结果与国外报道相符,进一步说明Binding-ELISA方法用于定性分析炭疽毒素与其受体结合能力的可行性,为评价以抑制PA与ATR结合为靶点的毒素抑制剂提供了有效的手段。 Objective: To establish a Binding-ELISA method for detecting the binding between anthrax protective antigen(PA) and anthrax toxin receptors (ATR). Methods: The Binding-ELISA was established on the basis of the indirect ELISA under optimal experimental conditions. In the Binding-ELISA assay, via the different coated proteins or bivalent cations, the characteristics of binding of PA and ATR were analyzed by the parameter of D450 and relative saturation. Results and Conclusion: When PA was used as coated protein at 2μg/ml, and the concentration of cation was 5 mmol/L, the assay was more sensitive. The potency of binding between PA and CMG2 was more powerful in the presence of calcium cation and that of binding between PA and TEM8 was higher in the buffer containing manganous cation. Moreover, the ability of binding between PA and CMG2 exceeded that of PA and TEM8. Thus recombinant CMG2 or its excellular portion and the mutant of CMG2 may be the next-generation toxin inhibitor.The Binding-ELISA assay contributes to the research on binding mechanisms of ATR and PA and offers an effective way for evaluating the new opportunity for anthrax by restraining the binding of PA and ATR.
出处 《军事医学科学院院刊》 CSCD 北大核心 2008年第5期428-431,共4页 Bulletin of the Academy of Military Medical Sciences
基金 国家自然科学基金资助项目(30571745)
关键词 炭疽毒素 炭疽保护性抗原 炭疽毒素受体 酶联免疫吸附试验 anthrax toxin anthrax protective antigen anthrax toxin receptor ELISA
  • 相关文献

参考文献18

  • 1Smith H, Keppie J. Observations on experimental anthrax: demonstration of a specific lethal factor produced in vivo by Bacillus anthracis [J]. Nature, 1954, 173(4410):869-870.
  • 2Stanley JL, Smith H. Purification of factor I and recognition of a third factor of the anthrax toxin [ J]. J Gen Microbiol, 1961, 26( 1 ) :49 -63.
  • 3Bradley KA, Mogridge J, Mourez M, et al. Identification of the cellular receptor for anthrax toxin [ J ]. Nature, 2001, 414 (6860) :225 - 229.
  • 4Scobie H, Rainey GJ, Bradley KA, et al. Human capillary morphogenesis protein 2 functions as an anthrax toxin receptor [ J ]. Proc Natl Acad Sci USA, 2003, 100(9) :5170 -5174.
  • 5Abrami L, Reig N, van der Goot FG. Anthrax toxin: the long and winding road that leads to the kill [ J]. Trends Microbiol, 2005, 13(2) :72 -78.
  • 6Mourez M. Anthrax toxins [ J ]. Rev Physiol Biochem Pharmacol, 2004, 152(1) : 135 -164.
  • 7Sherer K, Li Y, Cui XZ, et al. Lethal and edema toxins in the pathogenesis of Bacillus anthracis septic shock [ J]. Am J Respir Crit Care, 2007, 175(3) : 211 -221.
  • 8Rainey GJ, Young JA. Antitoxins : novel strategies to target agents of bioterrorism [J]. Nat Rev Microbiol, 2004, 2(9): 721 -726.
  • 9Panchal RG, Hermone AR, Nguyen TL, et al. Identification of small molecule inhibitors of anthrax lethal factor [ J ]. Nat Struct Mol Biol, 2004, 11 ( 1 ) : 67 - 72.
  • 10Sarac MS, Peinado JR, Leppla SH, et al. Protection against anthrax toxemia by hexa-D-arginine in vitro and in vivo [ J 1. Infect Immun,2004,72( 1 ) : 602 -605.

二级参考文献21

  • 1[1]Swanson-Biearman B,Krenzelok EP.Delayed life-threatening reaction to anthrax vaccine.J Toxicol Ciln Toxicol,2001,39(1):81-84
  • 2[2]Demicheli V,Rivetti D,Deeks JJ et al.The effectiveness and safety of vaccines against human anthrax:a systematic review.Vaccine,1998,16(9-10):880-884
  • 3[3]Baillie L.The development of new vaccines against Bacillus anthracis.J Appl Microbiol,2001,91:609-613
  • 4[4]Leppla SH.Development of an improved vaccine for anthrax.J Clin Invest,2002,110(2):141-144
  • 5[5]Enserink M,Marshall Eliot.New anthrax vaccine gets a green light.Science,2002,296:639-640
  • 6[6]Singh Y,Leppla SH,Bhatnagar R et al.Internalization and processing of lethal toxin by toxin-sensitive and-resistant cells.J Biol Chem,1989,264(19):11099-11102
  • 7[7]Kobiler D,Gozes Y,Rosenberg H et al.Efficiency of protection of guinea pigs against infection with Bacillus anthracis spores by passive immunization.Infect Immun,2002,70(2):544-550
  • 8[8]Ivins BE,Pitt ML,Fellows PF et al.Comparative efficacy of experimental anthrax vaccine candidates against inhalation anthrax in rhesus macaques.Vaccine,1998,16:1141-1148
  • 9[9]Singh Y,Ivins BE,Leppla SH et al.Study of immunization against anthrax with the purified recombinant protective antigen of Bacillus anthracis.Infect Immun,1998,66:3447-3448
  • 10Bradley K A, J A Young. Anthrax toxin receptor proteins. Biochem.Pharmacol, 2003, 65 (3): 309~314

共引文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部